Company / SG&A per Share
Viridian Therapeutics, Inc.\DE SG&A per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.75
FY2024
5-year range
$0.75 / $2.17
FY2020-FY2024
Trend
-64.5%
vs FY2023
Sector context
#140 of 210
Health Care
What the data says
At $0.75, Viridian Therapeutics, Inc.\DE's sg&a per share ranks #71 of 210 in the Health Care sector. SG&A per Share has fluctuated over the past 9 years, ranging from $0.37 in FY2018 to $13.09 in FY2017.
Based on SEC 10-K filings.
0.75 in FY2024 with a 5-year CAGR of -33.0%.
Improved from $1.10 to $0.75 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -29.6%
- 5-Year CAGR
- -33.0%
- 10-Year CAGR
- -
Sector benchmark
#71 of 210 in Health CareTop 33% of 210This company $0.75 Sector average $40.75
▼
-98.1% below sector average
Key checks
Key Insights
- In FY2024, sg&a per share decreased 64.5% year-over-year.
- Ranks #140 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2017.
- Lowest sg&a per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $0.75 | -64.5% |
| FY2023 | $2.12 | +93.6% |
| FY2022 | $1.10 | -49.4% |
| FY2021 | $2.17 | -41.9% |
| FY2020 | $3.73 | -33.1% |
| FY2019 | $5.57 | +1393.5% |
| FY2018 | $0.37 | -97.1% |
| FY2017 | $13.09 | +37.0% |
| FY2016 | $9.55 | +369.7% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026